stockrow
Friday 6 November 2026
Export QUCY’s income statement to Excel — free account
Quantum Cyber N.V
QUCY Healthcare Diagnostics & Research
Quantum Cyber N.V’s revenue for fiscal 2025 (year ended December 2025) was $537,100.00, down 39.9% from fiscal 2024.
- EPS
- +96.0%
- Free cash flow
- +26.7%
Quarter to June 2026, against a year earlier
0.70
0.04
−5.41%
Follow QUCY
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | 0 | 1 | 1 | 1 | 1 | 1 | 1 | +1.7% | 2 | 5 | 18 | +220.9% | |
| Gross margin, % | — | — | — | — | 24.94 | 30.76 | 34.38 | 56.92 | 64.31 | 72.57 | 56.91 | +47.6 pt | ||||||
| EBT | — | — | — | — | (1) | (12) | (26) | (26) | (22) | (16) | (21) | +94.2% | ||||||
| EBT margin, % | — | — | — | — | (118.90) | (2,024.96) | (4,979.68) | (2,936.43) | (2,415.97) | (3,018.19) | 0.00 | (2,899.3) pt | ||||||
| Net income | — | 0 | — | — | (1) | (12) | (26) | (26) | (22) | (16) | (19) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 3.52 | 3.20 | 1.50 | 2.21 | 0.91 | 0.09 | 0.00 | (52.0%) | |||||
| Earnings | — | — | — | — | (4.19) | (64.80) | (74.40) | (64.80) | (22.36) | (2.70) | (13.19) | (8.4%) | ||||||
| Cash flow | — | — | — | — | (3.34) | (17.86) | (41.73) | (54.02) | (17.58) | (1.83) | (0.92) | (11.3%) | ||||||
| Capex | — | — | — | — | (0.07) | (0.09) | (1.86) | (4.68) | (0.23) | (0.17) | (0.01) | +20.0% | ||||||
| Free cash flow | — | — | — | — | (3.41) | (17.95) | (43.59) | (58.70) | (17.82) | (2.00) | (0.93) | (10.1%) | ||||||
| Book value | — | — | — | — | (19.55) | 35.28 | 39.83 | 8.00 | 6.08 | 0.11 | 1.14 | n/m | ||||||
| Shares, m | — | — | — | — | 0 | 0 | 0 | 0 | 1 | 6 | 8 | +112.0% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | 0.00 | 0.00 | 176.32 | 21.22 | 1.96 | 4.29 | 13.95 | 34.0 | ||||||
| P/B | — | — | — | — | 21,588.83 | 784.67 | 6.63 | 5.85 | 0.00 | 5.99 | 0.62 | 3,732.0 | ||||||
| EV/Sales | — | — | — | — | 0.00 | 0.00 | 145.92 | 20.14 | 8.60 | 5.27 | 0.78 | 30.0 | ||||||
| EV/FCF | — | — | — | — | 0.00 | 0.00 | (5.01) | (0.76) | (0.30) | (0.23) | (0.04) | (1.1) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | 0 | (3) | (15) | (22) | (17) | (11) | (16) | +87.9% | |||||
| Capex | — | — | — | — | 0 | 0 | (1) | (2) | 0 | (1) | 0 | +154.4% | ||||||
| Free cash flow | — | — | — | — | 0 | (3) | (15) | (24) | (18) | (12) | (17) | +90.5% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | (1) | 8 | 14 | 0 | 2 | (2) | 14 | +29.1% | |||||
| Net debt | — | — | — | — | 1 | (8) | (16) | (1) | (4) | 0 | (13) | (26.4%) | ||||||
| Shareholders’ equity | — | — | — | — | (3) | 6 | 14 | 3 | 6 | 1 | 20 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | (174.34) | (218.22) | (174.28) | (147.52) | (149.42) | (172.19) | (165.20) | +2.2 pt | |||||
| ROIC | — | — | — | — | 0.00 | 0.00 | 0.00 | (730.26) | (651.38) | (1,219.26) | (193.99) | (1,219.3) pt | ||||||
| ROE | — | — | — | — | 0.00 | (645.93) | (257.97) | (303.20) | (467.15) | (488.32) | (325.19) | (488.3) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | 31 | 64 | 71 | 26 | 13 | — | (19.5%) | |||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.02 | 0.01 | 0.01 | 0.03 | 0.04 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Dec 2023 · fundamentals updated 25 Oct 2026
Quantum Cyber N.V vs peers in Diagnostics & Research (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| FLGT Fulgent Genetics, Inc. | $513.4M | — (loss-making) | — (loss-making) | +7.54% (above 0%: growing) | n/m | +2,058.74% (above 0%: growing) | 35.33% | (24.94%) | Compare |
| BDSX Biodesix, Inc. | $209.3M | — (loss-making) | — (loss-making) | +10.44% (above 0%: growing) | n/m | +12.78% (above 0%: growing) | 0.00% | (25.42%) | Compare |
| XGN Exagen Inc. | $184.1M | — (loss-making) | — (loss-making) | +15.92% (above 0%: growing) | n/m | +211.34% (above 0%: growing) | 61.27% | (8.64%) | Compare |
| BNR Burning Rock Biotech Limited Sponsored ADR | $116.5M | — (loss-making) | 11.1× | −4.22% (below 0%: shrinking) | n/m | +46.01% (above 0%: growing) | 72.58% | (13.36%) | Compare |
| MDXHF MedX Health Corp. | $103.2M | — (loss-making) | — (loss-making) | +33.59% (above 0%: growing) | n/m | +41.60% (above 0%: growing) | 37.19% | (1,027.95%) | Compare |
| IMDX Insight Molecular Diagnostics Inc. | $80.5M | — (loss-making) | — (loss-making) | −53.86% (below 0%: shrinking) | n/m | −54.02% (below 0%: shrinking) | 65.69% | (4,770.71%) | Compare |
| QUCY Quantum Cyber N.V | $60.8M | — (loss-making) | — (loss-making) | +11.12% (above 0%: growing) | n/m | +26.73% (above 0%: growing) | 62.71% | 0.00% | |
| PRPO Precipio, Inc. | $33.3M | — (loss-making) | 15.4× | +24.18% (above 0%: growing) | n/m | +79.59% (above 0%: growing) | 44.67% | (8.53%) | Compare |
| MDXH MDxHealth SA | $14.4M | — (loss-making) | — (loss-making) | +12.01% (above 0%: growing) | n/m | −200.20% (below 0%: shrinking) | 65.75% | (18.74%) | Compare |
| Median of peers | $109.8M | — | — | +11.23% | — | +43.81% | 52.97% | (21.84%) |
Pay and ownership Proxy statement filed 1 June 2026
Ownership
Directors and executive officers, together
95.70% of the votes
David Lazar, Chief Executive Officer and Director
95.60% of the votes
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement